What did @honeybthatsme actually say?
She said she lost 20 pounds in roughly one month on a GLP-1 medication, dropping from 174 to 152 pounds. She also claimed the medication is "regulating my mood," giving her more energy, improving her eating habits, and helping her hit protein goals. The caption on the video says she started at 172, but her own transcript puts the starting weight at 174. That two-pound discrepancy is minor but worth noting since the exact numbers are central to the claim.
She frames this as a personal update, not medical advice, and she does not name a specific drug or dose at any point. The video is sponsored by or affiliated with a platform called Freya. That relationship is disclosed in the caption but not verbally during the video itself, which is a transparency gap worth flagging for viewers.
Does the science back this up?
Twenty pounds in one month is possible early in GLP-1 treatment, but it is on the high end of what clinical data typically shows, and context matters a lot here.
The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that participants on semaglutide 2.4 mg lost an average of 14.9% of body weight over 68 weeks. In the first four weeks specifically, losses tend to be more dramatic because of rapid fluid shifts, reduced caloric intake, and GI side effects that suppress appetite acutely. A 2023 analysis in Obesity (Rubino et al.) confirmed that early rapid loss is common but often includes a significant water weight component that stabilizes over time.
Her mood and energy claims are harder to pin down. Some research, including a 2023 study in Nature Metabolism (Farr et al.), suggests GLP-1 receptors in the brain may influence reward pathways and mood. But calling a month of anecdotal experience proof of mood regulation is a stretch the data does not fully support yet.
What did they get right, and what is missing?
Credit where it is due: she mentions hitting protein goals, which aligns with clinical guidance. Adequate protein intake during GLP-1-assisted weight loss helps preserve lean muscle mass, something the drug itself does not do on its own. Research from Biolo et al. (1997, American Journal of Physiology) and more recent GLP-1-specific work consistently supports high protein intake during caloric restriction.
What she gets wrong, or at least incomplete, is attributing all of this to the medication alone. "This has just been regulating my mood" and "I'm waking up" and "life just feels amazing" are bundled together as drug effects, but behavioral changes, better sleep, improved diet, and the psychological boost of visible progress are all plausible contributors. She does not separate them, and that conflation could mislead viewers into thinking a GLP-1 is doing more neurological work than the evidence currently confirms.
She also does not mention side effects. GLP-1 medications have well-documented GI effects including nausea, vomiting, and constipation, and the absence of any mention in a sponsored-adjacent video is a notable omission.
What should you actually know?
Early weight loss on GLP-1 medications is real, but the first month often overstates what long-term results look like. Fluid loss, reduced gut motility, and acute appetite suppression drive dramatic early numbers. The clinical trials that support these medications measured outcomes over 52 to 72 weeks, not 30 days.
More importantly, GLP-1 medications work significantly better when combined with dietary changes and activity, which she does mention. But that also means her results are not purely pharmacological. Viewers who start a GLP-1 expecting identical outcomes without the behavioral changes she describes may be disappointed.
If you are considering a GLP-1 medication, the conversation should happen with a licensed clinician who reviews your full health history. A 20-pound testimonial on TikTok, even an honest one, is not a substitute for that evaluation. Compounded versions of semaglutide or tirzepatide, which many telehealth platforms dispense, are not equivalent to FDA-approved brand-name drugs in terms of regulatory oversight, and that distinction matters when making a treatment decision.